Overview

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2019-09-26

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus atezolizumab alone.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal
Atezolizumab
Daratumumab